MASSACHUSETTS GENERAL HOSPITAL

CENTER FOR FACULTY DEVELOPMENT

125 Nashua Street, Suite 8-8240
Boston, Massachusetts 02114
Tel: (617) 724-0818
Email: cfd@partners.org
https://www.massgeneral.org/faculty-development

Center for Faculty Development
Office for Clinical Careers
Office for Research Careers
  - Graduate Student Division
  - Post Doctoral Division
Office for Well-Being
Office for Women's Careers

SAMPLE CV NARRATIVE
ASSISTANT PROFESSOR
AoE CEI + SSA Inv

Overview

I am a cardiologist, clinical investigator, and educator, specializing in the care of patients with a broad spectrum of cardiovascular diseases, most notably heart failure and coronary artery disease. Since joining the faculty at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) in 2012, I have provided clinical care, conducted research in heart failure, and served as peer and trainee educator with the goal of improving clinical care.

Area of Excellence: Clinical Expertise and Innovation

I have developed expertise and clinical innovations in the field of biomarkers, heart failure and risk factors for heart failure including coronary artery disease and myocardial infarction. I receive referrals locally, regionally and nationally and see patients in both inpatient and outpatient settings.

My clinical work inspires many of my research questions and is a natural connection to my clinical research on biomarkers, heart failure and risk factors. My work on novel and established biomarkers, to improve diagnostic and prognostic performance, as well as how biomarkers may be used in heart failure management, set international standards for the clinical use of these biomarkers in heart failure. My work on natriuretic peptides directly led to establishing a globally standardized approach to interpreting natriuretic peptide levels for the diagnosis of acute heart failure and helped establish novel biomarkers, such as soluble ST2, as an innovative predictor of clinical outcomes. Independent from my work with my mentor on the role of biomarkers in diagnosis and prognosis, I have focused on how novel tools including biomarkers, digital health technology and advanced analytics such as machine learning may impact heart failure management. With the goal to advance precision medicine in heart failure, I evaluated novel ways to utilize established and novel biomarkers as well as digital tools in heart failure management such as using soluble ST2 to identify patients who particularly benefited from a specific heart failure medication or a Smartphone-based App to improve heart failure self-management. I have also garnered attention for my work on type 2 (demand-supply mismatch-related) myocardial infarction where I demonstrated that patients with type 2 myocardial infarction have poor prognosis similar to or worse than patients with traditional acute coronary artery thrombosis-related myocardial infarction. I have given invited presentations and lectures nationally and internationally regarding my work above. My innovative research findings have been recognized in national and international clinical practice guidelines and statements and influenced clinical practice globally. I am active in participating in local, national and international clinical trials as an investigator, key opinion leader, and member of scientific advisory boards and clinical end points committees.

I have broadened the scope of my research in my independently-funded research laboratory since 2015. Going beyond the traditional left ventricular ejection fraction-based heart failure groups, I

developed novel heart failure phenotypes using machine learning in a national Registry (submitted, under review). I plan to explore both biological and structural underpinning in heart failure phenotypes as well as interaction with therapy in the *Patients With Heart Failure With Preserved, Midrange and Reduced Ejection Fraction: Preserved vs. Reduced Ejection Fraction BiomEchanical Marker Registry for Ambulatory Heart Failure Patients (PREFER-HF) Registry* (1,313 patient enrollment completed in 2020). I am also focusing on heart failure with preserved ejection fraction including cardiac amyloidosis as a distinct entity in the *Prevalence and Prediction of Transthyretin Amyloidosis in Patients with Heart Failure with Preserved Ejection Fraction Study* (funded and enrolling since 2020).

Significant Supporting Activity: Investigation

I am active in clinical investigation in the area of heart failure. My H-index is 35 with 73 original publications (12 as first author and four as senior author), 30 reviews/chapter/editorials and two textbooks. I am the PI or co-PI on four active grants including a grant that is equivalent to an NIH R-level grant. I have presented my research in heart failure at outside institutions, national and international scientific meetings. I am a part of Data Safety Monitoring Boards for NIH trials and clinical endpoints committees for national and international clinical trials. I also served as a Faculty Investigator for the Harvard Clinical Research Institute (now Baim Institute for Clinical Research), an academic research organization, before continuing in my role as a consultant and clinical endpoints committee member. I am a reviewer for many of high impact heart failure and general cardiology journals and serve as an Editorial consultant for the JACC: heart failure and Associate Editor for the International Journal of Cardiology.

Teaching

I lead peer and trainee education at the local, regional, national and international level through my work as the founder, editor or course director of textbooks (MGH Cardiology Board Review Book 1st and 2nd edition) and of live (MGH Cardiology Board Review Course) and on demand (Advanced Cardiology with HMS) cardiology education programs. In my role as the Subspecialty Core Educator for Cardiology for the Department of Medicine Residency Program, I set up the Cardiology Ambulatory blocks and lectures and mentor residents interested in cardiology.

Summary

My goal is to provide excellent clinical care, research, and education to trainees and peers alike in my area of clinical expertise of biomarkers, heart failure, and risk factors for heart failure. My clinical activity provides a natural connection to my research in heart failure. Over the next years I will continue working to improve patient care through my clinical practice and research and train the next generation of cardiology specialists.